Blog

Barend Sikkema: Body weight gain associated with alectinib in patients with ALK positive NSCLC

Barend Sikkema/LinkedIn

Dec 13, 2024, 15:35

Barend Sikkema: Body weight gain associated with alectinib in patients with ALK positive NSCLC

Barend Sikkema, PHD Candidate at Erasmus MC, shared a recent article on LinkedIn:

“Publication Alert.

Our latest article titled Body weight gain associated with alectinib in patients with ALK positive non-small cell lung cancer: pooled analysis of individual patient data from 4 prospective clinical trials, is now available online in the Journal of Clinical Oncology.

Aim: To analyze body weight changes over time and investigate whether baseline patient characteristics are linked to changes in weight.

Key findings:

49% of patients experienced ≥ 5% body weight gain, and 18% gained ≥ 10% during alectinib treatment. Off note, weight gain is not reported in similar effective SMKI’s such as osimertinib in EGFR positive NSCLC.
Notably, follow-up body weights were not systematically recorded in the landmark ALEX trial.
No readily available clinical baseline characteristic was clinically meaningful associated with weight gain, making it challenging to identify patients at risk before start of treatment.

Our study reveals the underreporting of body weight gain in clinical trials and our findings emphasize the need for greater awareness among clinicians of this overlooked adverse event.

Takeaway for clinicians: Monitor body weight changes and preferably also waist circumference – closely in patients on alectinib.”

Title: Body Weight Gain Associated With Alectinib in Patients With ALK+ Non–Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials

Authors: Barend J. Sikkema, Sara J. Baart, Marthe S. Paats, Egbert F. Smit, Annemie MWJ Schols, Ron HJ Mathijssen, Elisabeth FC van Rossum and Anne-Marie C. Dingemans

Barend Sikkema

For more updates, follow OncoDaily.

alectinib ALK-positive NSCLC Annemie M.W.J. Schols ASCO Barend J. Sikkema body weight cancer clinical trials Egbert F. Smit Elisabeth F.C. van Rossum Journal of Clinical Oncology Marthe S. Paats OncoDaily Oncology osimertinib patients Ron H.J. Mathijssen Sara J. Baart

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer